MAP Pharmaceuticals, Inc. uses inhalation technologies to improve the therapeutic benefits and commercial attractiveness of drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company have several product candidates in the clinical development, which address the market opportunities, including the unit dose budesonide (UDB), for the treatment of asthma in children and MAP0004 for the treatment of migraine. In December 2008, MAP Pharmaceuticals and AstraZeneca AB (AstraZeneca) entered into a global collaboration to develop and commercialize UDB. UDB is the nebulized version of budesonide intended to treat asthma in children from 12 months to eight years of age. UDB is marketed by AstraZeneca, under the brand name Pulmicort Respules. MAP0004 is orally inhaled version of dihydroergotamine (DHE) to treat migraine.